Document is current
Any future updates will be listed below
-
Authors
Chanoumidou, Konstantina
Zota, Ioanna
Papadopoulou, Maria Anna
Konstantinou, Chrystalla
Tsimpolis, Alexandros
Tsagliotis, Electra
Tziortziou, Maria
Ntarntani, Katerina
Grünewald, Anne
Lavigne, Matthieu David
Gravanis, Achille
Charalampopoulos, Ioannis
-
Funding
Funding for this research was provided by:
Bodossaki Postdoctoral Research Fellowship
EMBO Scientific Exchange Grant (STF_11143)
Fonds National de la Recherche Luxembourg (PRIDE21/16749720)
Luxemburg National Research Fund (FNR9631103)
European Union – NextGenerationEU (TAEDR-0535850)
European Union HORIZON (No 101099145)
Institute of Pharmaceutical Research and Technology
- License Information
-
More Information
Article History
Received: 22 July 2025
Accepted: 3 March 2026
First Online: 21 March 2026
Declarations
:
: The human iPSC lines provided by Dr Μ. Z. Cader were derived from human skin biopsy fibroblasts, following signed informed consent, with approval from the UK NHS Research Ethics Committee (REC: 13/SC/0179 and 10/H0505/71, Study Title: Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC), Date 09/05/2013) and were derived as part of the IMI-EU sponsored StemBANCC consortium. The human iPSC line provided by Prof. Grünewald was derived from female donor fibroblasts, following research consent from the patient and “CNER” stands for Comité National d’Ethique de Recherche (CNER N° 201411, Study Title: Disease modelling of Parkinson’s disease using patient-derived fibroblasts and induced pluripotent stem cells (DiMo-PD), Date 04/10/2023).
: Not applicable.
: The authors declare that they have not use AI-generated work in this manuscript.
: All authors, except Achille Gravanis, declare that they have not any competing financial interests in relation to the work described. Dr Achille Gravanis is the co-founder of spin-off Bionature EA LTD, proprietary of compound BNN27 (patented with the WO 2008/ 1555 34 A2 number at the World Intellectual Property Organization). Gravanis A is co-founder of Bionature E.A. Ltd. The BNN compounds are proprietary and patented by the Bionature E.A. Ltd (http://www.bionature.net) (Patent Number: WO2008/155534 A2).
